Growth-hormone axis · Peptide
Tesamorelin
Also known as Egrifta
Stimulates the body's own growth hormone to reduce deep visceral belly fat.
Status as of 2026-07 · reclassification ≠ FDA approval · educational only, not medical advice.
The signal it sends
A GHRH analog prompting the pituitary to release GH in natural pulses.
Benefits & effects studied
- Reduces visceral fat
- May improve liver fat
- Supports lean mass
Research state
Approved for HIV-associated visceral fat; studied for fatty liver.
Dosing & pharmacokinetics
Daily subcutaneous injection. Half-life: ~26 minutes (daily dosing).
Dosing information is educational only. Tesamorelin decisions belong with a licensed clinician — Jevity does not recommend or supply dosing.
History & discovery
First described 2000s by Theratechnologies Inc. Origin: Developed by Canadian firm Theratechnologies (as TH9507) as a stabilized growth-hormone-releasing factor analog; FDA-approved in 2010 (as Egrifta) to reduce excess abdominal fat in HIV patients with lipodystrophy..
Molecular structure
A synthetic 44-amino-acid peptide identical to human GHRH, with an added trans-3-hexenoic acid group for greater stability.
Frequently asked questions
Is Tesamorelin FDA-approved?
FDA-approved (Egrifta®) On Jevity's evidence scale, Tesamorelin is graded "FDA-approved". Reclassification for compounding is not the same as FDA approval.
What is Tesamorelin used for?
Stimulates the body's own growth hormone to reduce deep visceral belly fat. A GHRH analog prompting the pituitary to release GH in natural pulses. Studied effects include: Reduces visceral fat; May improve liver fat; Supports lean mass. This is educational information, not a recommendation to use it.
Is Tesamorelin legal in the UAE?
UAE / DHA status: Prescription medicine — DHA-licensed provider
Is Tesamorelin banned in sport?
WADA status: Prohibited at all times (GH axis)
What is Tesamorelin's Jevity Score?
Tesamorelin has a Jevity Score of 93/100 — a proprietary composite of evidence strength (10/10), regulatory clarity (9/10) and supply verifiability (8/10). It reflects how established and legitimate the compound is, not a recommendation.
Related growth-hormone axis peptides
Educational information only — not medical advice, a diagnosis, or a recommendation to use any substance or therapy. Regulatory status changes; verify current rules and any personal decision with a licensed clinician. Jevity is operated by Upcapital Global FZCO, Dubai, UAE.